Caplin Point Laboratories

About Caplin Point Laboratories

Caplin Point Laboratories Limited, established in 1990, specializes in manufacturing a range of pharmaceutical products including ointments, creams, and other external applications. The company went public in 1994, with its IPO being oversubscribed 117 times, which funded the establishment of a manufacturing facility in Pondicherry. Over the years, Caplin Point has expanded its product range and production capacity, focusing on innovative technologies and products. The company operates a unique business model by owning distribution networks, primarily serving the Bottom of the Pyramid markets. This approach allows Caplin Point to cater to underserved regions with affordable and effective pharmaceutical solutions. The company's facility has been inspected by the US FDA three times since 2016, receiving Establishment Inspection Reports (EIR) each time. As of now, Caplin Point has filed 20 Abbreviated New Drug Applications (ANDAs) with 18 approvals, 12 of which belong to Caplin Steriles. The company invests a significant portion of its earnings into Research and Development to ensure the creation of safe and effective products across various dosage forms. Caplin Point's business model generates revenue through the manufacturing and distribution of generic drugs, catering to both domestic and international markets, with a strong emphasis on affordability and accessibility.